|
|
||||||||
Brief Report |
From the Department of Neurology, University of California at Los Angeles, Los Angeles, CA.
Objective: The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD).
Methods: Twelve patients with FTD who received donepezil for six months were compared with 12 FTD controls on behavioral measures.
Results: The groups did not differ on most variables at baseline or at six months; however, the donepezil group had greater worsening on the FTD Inventory. Four treated patients had increased disinhibited or compulsive acts, which abated with discontinuation of the medication.
Conclusion: There were no changes in global cognitive performance or dementia severity; however, a subgroup of patients with FTD can experience worsening of symptoms with donepezil.
Key Words: Frontotemporal dementia donepezil acetylcholinesterase inhibitors
This article has been cited by other articles:
![]() |
L. Massimo and M. Grossman Patient Care and Management of Frontotemporal Lobar Degeneration American Journal of Alzheimer's Disease and Other Dementias, May 1, 2008; 23(2): 125 - 131. [Abstract] [PDF] |
||||
![]() |
M. F. Mendez, E. C. Lauterbach, S. M. Sampson, and ANPA Committee on Research An Evidence-Based Review of the Psychopathology of Frontotemporal Dementia: A Report of the ANPA Committee on Research J Neuropsychiatry Clin Neurosci, May 1, 2008; 20(2): 130 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Caselli and R. Yaari Medical Management of Frontotemporal Dementia American Journal of Alzheimer's Disease and Other Dementias, January 1, 2008; 22(6): 489 - 498. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |